The Significance of Selective Estrogen Receptor Modulators as Potential Multifaceted Therapeutic Agents

***Dr. Anju Sharma**

Abstract

Selective estrogen receptor modulators (SERMs) refer to a category of drugs that possess diverse chemical structures. These drugs exhibit a high affinity for estrogen receptors (ERs), but their unique characteristic lies in their ability to elicit either estrogen-like or estrogen-blocking effects, depending on the specific tissue they target. It is important to distinguish SERMs from pure antiestrogens like fulvestrant, which are chemically similar to estradiol and exclusively display estrogen-blocking properties. Additionally, SERMs should not be confused with "gonad mimetic" drugs such as tibolone, which interact with various sex steroid receptors through non-selective binding. Several new groups of synthetic compounds, known as Selective Estrogen Receptor Modulators (SERMs), have been identified and are currently in use or undergoing clinical evaluation. Furthermore, numerous new compounds are being reported in patent literature. Although clinical trial data on these novel compounds are limited, they are being studied for their potential in preventing and treating hormone-responsive cancers, managing post-menopausal osteoporosis, and addressing estrogen deficiency-related indications such as cardiovascular disease.

Keywords: Fulvestrant, hormone-responsive cancer, osteoporosis, and gonad-mimetic medicines

INTRODUCTION

Small molecules produced by naturally occurring hormones affect the control of gene expression through intracellular receptors (IRs). It is possible to affect cell proliferation, cell differentiation, and other cellular processes because certain tiny compounds have the capacity to imitate (agonism) or hinder (antagonism) the activities of natural hormones. IRs, including sex steroid receptors (mostly oestrogen), are hence desirable drug development targets.

The creation of novel medications and other biologically active substances has traditionally depended on chance encounters. In order to create the perfect medicine, a huge number of structural analogues are often synthesised once a "lead compound" has been successfully found. These structural analogues are then tested in multiple in vitro and in vivo models.

Over the last several decades, there has been a lot of interest in the creation of substances that might mitigate the biological effects of oestrogens. Such substances are referred to be estrogen antagonists by both the pharmaceutical and academic research communities as possible therapeutic agents.

SERMs interact with oestrogen receptors and have tissue-specific effects according to their diverse structural makeup. These substances have special chemical features that enable them to bind to

oestrogen receptors with a high degree of affinity, modulating the activity of the receptors that control transcription. SERMs may elicit agonist or antagonist responses, simulating or suppressing the activities of oestrogen by specifically targeting certain oestrogen receptor subtypes (ER or ER) in various organs.

The importance of SERMs is seen in their broad therapeutic applications for a range of illnesses. The use of SERMs in the prevention and treatment of malignancies like breast and endometrial cancer that respond to hormones is one of their most well-known uses. Breast tissue oestrogen receptors are negatively impacted by SERMs, which lowers the risk of estrogen-induced proliferation and the prevalence of breast cancer. For post-menopausal women with osteoporosis, however, SERMs may have agonistic effects on bone tissue, improving bone mineral density and lowering the risk of fractures.

SERMs have shown potential in the prevention of cardiovascular disorders in addition to their roles in cancer and bone health. Since low levels of oestrogen have been linked to negative cardiovascular consequences, SERMs may be able to protect the heart by regulating lipid metabolism, enhancing endothelial function, and lowering inflammation.

The potential of SERMs in additional oestrogen deficiency-related indications, such as menopausal symptoms, neuroprotection, and cognitive performance, is also being investigated in current research. These substances provide a flexible method to treat a variety of medical disorders linked to hormonal imbalances and oestrogen deficiency.



Figure 1. The concept of estrogen receptor modulation: Development of Selective Estrogen Receptor Modulators (SERMs).

The Significance of Selective Estrogen Receptor Modulators as Potential Multifaceted Therapeutic Agents

Dr. Anju Sharma

The development of tissue-selective drugs has involved the creation of new ligands that possess the ability to selectively target specific tissues. This approach aims to retain the beneficial effects of estrogen on non-traditional target tissues while minimizing concerns related to estrogen-positive cancers. The complexity arises from the fact that estrogenic ligands can interact with multiple potential target tissues and induce varying physiological responses. Consequently, novel compounds with different structural properties have been identified, which bind to estrogen receptors (ER). These compounds exhibit selective differences in binding affinity and transcriptional efficacy for different ER subtypes (ERα or ERβ). Depending on the specific target tissue and hormonal environment, these compounds can function as agonists or antagonists. They are referred to as selective estrogen receptor modulators (SERMs) because they have the ability to selectively modify the activity of the estrogen receptor in specific cells. This makes them the quintessential pharmacological treatment based on a single molecular target. In the skeletal, cardiovascular, and neurological systems, SERMs may mimic estrogen's actions (agonist effect), while exerting almost complete antagonism in the breast and uterine tissues (Figure 1; Table 1). A chemical compound can be classified based on its ability to produce a cell-selective agonist-antagonist response.

Classification	Genitourinary and reproductive tissue	Skeletal, cardiovascular and central nervous system	Examples
Agonists	Yes	Yes	Di-ethyl stilbestrol, hexasterol
Partial agonist/ antagonists	Yes/No	Yes	Tamoxifen, Clomiphene
SERMs	No	Yes	Raloxifen, CP-336156
Antagonists	No	No	ICI-182, 790 ICI-164, 385

Table 1. Classification of estrogen receptor modulators

SERM SALIENT FEATURES

1. Due to their ability to a) Significantly enhance bone mineral density (BMD), they may be employed in the prevention and treatment of osteoporosis .

b) The reduction of fracture occurrences and the prevention of bone loss.

2. They may also be utilised to prevent and treat cardiovascular disorders due to the actions of their agonists, which have shown the following benefits:

Reduce serum fibrogen and serum cholesterol, especially low density lipoprotein cholesterol (LDL-C), by inhibiting the formation of cholesteron.a) Reduce the initial thickness of the carotid arteries and aortic lipid buildup in the event of injury.

b) Reduces membrane fluidity and inhibits lipid peroxidation.

c) Stop the progression of atherosclerosis in the coronary arteries.

3. They contain the following characteristics and may be used to prevent and treat malignancies that are sensitive to estrogen because of their antagonistic features.

Aside from having anti-breast cancer qualities, it also has an antagonistic impact on the uterus that doesn't promote endometrial hyperplasia.

b) Decreased likelihood of lever carcinogenesis.

4. Through an agonist action, they have been proven to enhance brain cognitive performance and alleviate postmenopausal depression and Alzheimer's disease.

With this family of compounds, innovative estrogen medicines may be created as tissue-selective drugs in the new century for the treatment and prevention of a variety of illnesses linked to oestrogens.

CONCLUSION

Tamoxifen and toremifene's antineoplastic activity in estrogen-dependent breast cancer and raloxifene's positive effects on bone remodelling, bone mineral density, and the reduction of osteoporotic fractures in postmenopausal women are the main pharmacodynamic characteristics of the SERMs that are currently on the market. The Women's Health Initiative results have raised interest in the entire therapeutic potential of SERMs, which has yet to be fully explored, due to their ability to preserve some of estrogen's positive effects while mostly avoiding its negative ones. The great intricacy of the many illnesses that SERMs may affect makes this investigation a significant, time-consuming, and expensive undertaking. Regarding this, raloxifene clinical studies that are almost finished will provide more information in the next years on the possible use of this SERM in postmenopausal women's primary prevention of breast cancer and cardiovascular disease. The promising early findings on novel SERMs like lasofoxifene, bazedoxifene, arzoxifene, ospemifene, etc. still need to be verified in the extensive clinical studies that are now being conducted. It is easy to

make assumptions about the desired pharmacological properties of a selective estrogenreceptor modulator given what we now know about these medications.

***Department of Chemistry**
Government Govt. Girls College
Ajmer (Raj.)

REFERENCES

1. Hajela K, et al. Non-Steroidal Estrogen Antagonists; Present status and Future perspectives. Curr Med Chem Immunol Endocrinol Metabolic Agents 2001;1:235-256.
2. Pandey J. Significance of Synthetic SERMs in Women's Health. Editorial-Organic Chem Curr Res 2013;2:2.
3. Pandey J and Avidha K. Raloxifene: An Effective Selective Estrogen Receptor Modulator. Ecronicon Chemistry Journal 2015;2:92-96.
4. Jordan VC. The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 1992;70:977-982.
5. Jordan VC. Designer estrogens. Scientific American 1998;279:60-67.
6. Gustafsson JA. Therapeutic potential of selective estrogen receptor modulators. Curr Opin Chem Biol 1998;2:508-511.
7. Wakeling AE. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocrine-Related Cancer 2000;7:17-28.
8. Webb P, et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443–456.
9. Webb P, et al. The estrogen receptor enhances AP-1 activity by two Distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 1999;13:1672-1685.
10. Paech K, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP1 sites. Science 1997;277:1508–1510
11. Montano MM and Katzenellenbogen BS. Identification of a novel cis-acting element in the promoter of an estrogenresponsive gene that modulates sensitivity to hormone and antihormone. Proc Natl Acad Sci USA 1997;94:2581–2585.